This Month in JNM

PET/CT staging in NSCLC: Gregory and colleagues detail the effect on management and prognostic value of ¹⁸F-FDG PET/CT staging in patients with non–small cell lung cancer being considered for potentially curative therapies.Page 1007

PET and RCTs: Scheibler and colleagues provide an overview of the numbers, clinical topics, design, and quality of current randomized controlled trials evaluating PET and PET/CT.Page 1016

Hybrid sentinel node mapping: Buckle and colleagues describe intraprostatic injection of indocyanine green–^99mTc-nanocolloid to enable both preoperative sentinel node identification and intraoperative visualization.Page 1026

Hybrid sentinel node tracer validation: Brouwer and colleagues compare the lymphoscintigraphic drainage patterns of fluorescent indocyanine green and ^99mTc-nanocolloid with the drainage pattern of ^99mTc-nanocolloid alone in patients with melanoma or penile carcinoma.Page 1034

Noise considerations in PET quantification: Lodge and colleagues measure aspects of bias and reproducibility associated with maximum and peak ¹⁸F-FDG PET SUVs using clinical treatment monitoring data to provide realistic noise contexts.Page 1041

Response assessment with ¹⁸F-FET PET: Galldiks and colleagues explore the predictive value of ¹⁸F-FET PET in determining treatment response in glioblastoma and compare results with those obtained using MRI.Page 1048

Recurrent gliomas and ¹¹C-AMT PET: Alkonyi and colleagues evaluate the utility of α-¹¹C-methyl-l-tryptophan PET supplemented by tracer kinetic analysis for distinguishing recurrent gliomas from radiation injury.Page 1058

¹⁸F-FE-PE2I in humans: Sasaki and colleagues look at quantification of dopamine transporters in human volunteers, with a new PET radioligand that in animal studies has shown fast kinetics and low production of radiometabolites.Page 1065

PET and MRI in SCA17: Brockmann and colleagues assess functional and morphologic imaging characteristics to identify evidence of neurodegeneration in early stages of spinocerebellar ataxia type 17, a rare autosomal disorder.Page 1074

Calcium score and preoperative risk: Ghadri and colleagues research the added value of coronary artery calcium score as an adjunct to SPECT myocardial perfusion imaging for cardiac risk stratification before noncardiac surgery.Page 1081

¹²³I-FP-CIT SPECT SERT measurement: Koopman and colleagues examine the extrastriatal binding of this agent commonly used to assess striatal dopamine transporter binding to determine optimal time points for SPECT measurement of serotonin transporter binding.Page 1087

Imaging multiple myeloma: Walker and colleagues present an educational overview of imaging of multiple myeloma and related plasma cell dyscrasias, including the role of advanced imaging in diagnosis, staging, and restaging.Page 1091

Quantitative in vivo PET/MR: Ng and colleagues describe and evaluate the ability of a first-generation, small-animal MRI-compatible PET scanner to accurately depict heterogeneous patterns of radiotracer uptake in tumors.Page 1102

¹⁸F-Affibody for EGFR imaging: Miao and colleagues report on the successful site-specific labeling of an Affibody analog for PET imaging of epidermal growth factor receptors and review the potential for translation to clinical use.Page 1110

ER/PR PET and endocrine therapy: Fowler and colleagues use estrogen- and progestin-based radiopharmaceuticals to image estrogen receptor-α and progesterone receptor in mouse mammary tumors during hormonal therapy to determine whether changes can predict therapeutic response.Page 1119

Folate receptor-α–specific targeting ligand: Vaitilingam and colleagues detail the development of a reduced and alkylated form of folic acid for use in a targeting ligand to selectively deliver attached imaging and therapeutic agents to tumor cells.Page 1127

Growth dynamics of glioblastomas: Viel and colleagues use multimodal small animal PET and MRI to analyze the growth of angiogenesis-dependent and -independent experimental glioblastomas at various stages.Page 1135

PARP-1 and ¹³¹I-MIBG/topotecan: McCluskey and colleagues report on the potential of polyadenosine diphosphate ribose polymerase inhibition as a means to enhance targeted therapy with ¹³¹I-MIBG and the topoisomerase I inhibitor topotecan.Page 1146

No-carrier-added ¹³¹I-MIBG: Matthay and colleagues establish the maximum tolerated dose of no-carrier-added ¹³¹I-MIBG in patients with resistant neuroblastoma and assess tumor and organ dosimetry and overall response.Page 1155

ON THE COVER

Estrogen receptor-α and progesterone receptor are expressed in most human breast cancers and are important predictive factors for directing therapy. A preclinical study in this issue of JNM demonstrates that imaging baseline tumoral ¹⁸F-FES uptake and initial changes in ¹⁸F-FFNP uptake is a potentially useful, noninvasive strategy to identify responders and nonresponders to endocrine therapy at an early stage.

See page 1121.

• © 2012 by the Society of Nuclear Medicine, Inc.